Skip to main content

Advertisement

Articles

Page 1 of 35

  1. Insulin resistance may contribute to aortic stiffening that leads to end-organ damage. We examined the cross-sectional association and prospective association of insulin resistance and aortic stiffness in olde...

    Authors: Anna K. Poon, Michelle L. Meyer, Hirofumi Tanaka, Elizabeth Selvin, James Pankow, Donglin Zeng, Laura Loehr, Joshua W. Knowles, Wayne Rosamond and Gerardo Heiss

    Citation: Cardiovascular Diabetology 2020 19:11

    Content type: Original investigation

    Published on:

  2. Although a variety of antidiabetic drugs have significant protective action on the cardiovascular system, it is still unclear which antidiabetic drugs can improve ventricular remodeling and fundamentally delay...

    Authors: Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang and Feng Jiang

    Citation: Cardiovascular Diabetology 2020 19:10

    Content type: Original investigation

    Published on:

  3. To examine the incidence of atrial fibrillation in individuals with type 2 diabetes compared with age- and sex-matched controls from the general population and its variation in relation to glycaemic control an...

    Authors: Shilan Seyed Ahmadi, Ann-Marie Svensson, Aldina Pivodic, Annika Rosengren and Marcus Lind

    Citation: Cardiovascular Diabetology 2020 19:9

    Content type: Original investigation

    Published on:

  5. Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed...

    Authors: M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser and M. Arad

    Citation: Cardiovascular Diabetology 2020 19:7

    Content type: Original investigation

    Published on:

  6. The effect of sodium glucose cotransporter type 2 (SGLT2) inhibitor on left ventricular (LV) longitudinal myocardial function in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) has remained un...

    Authors: Hidekazu Tanaka, Fumitaka Soga, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi and Ken-ichi Hirata

    Citation: Cardiovascular Diabetology 2020 19:6

    Content type: Original investigation

    Published on:

  7. While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of ...

    Authors: Salva R. Yurista, Herman H. W. Silljé, Michiel Rienstra, Rudolf A. de Boer and B. Daan Westenbrink

    Citation: Cardiovascular Diabetology 2020 19:5

    Content type: Commentary

    Published on:

  8. This study investigated whether visit-to-visit fasting plasma glucose (FPG) variability, as measured by the coefficient of variation (CV), increased peripheral artery disease (PAD) risk.

    Authors: Chun-Pai Yang, Cheng-Chieh Lin, Chia-Ing Li, Chiu-Shong Liu, Chih-Hsueh Lin, Kai-Lin Hwang, Shing-Yu Yang and Tsai-Chung Li

    Citation: Cardiovascular Diabetology 2020 19:4

    Content type: Original investigation

    Published on:

  9. Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional...

    Authors: William A. E. Parker, Christian Schulte, Temo Barwari, Fladia Phoenix, Sam M. Pearson, Manuel Mayr, Peter J. Grant, Robert F. Storey and Ramzi A. Ajjan

    Citation: Cardiovascular Diabetology 2020 19:3

    Content type: Original investigation

    Published on:

  10. Peroxisome proliferator-activated receptor-γ (PPAR-γ) modulating treatment may have cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients after ischemic stroke (IS). However, whether there are ad...

    Authors: Chi-Hung Liu, Tsong-Hai Lee, Yu-Sheng Lin, Pi-Shan Sung, Yi-Chia Wei and Yan-Rong Li

    Citation: Cardiovascular Diabetology 2020 19:2

    Content type: Original investigation

    Published on:

  11. Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagli...

    Authors: Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii, Takahisa Hirose and Naoki Kumashiro

    Citation: Cardiovascular Diabetology 2020 19:1

    Content type: Original investigation

    Published on:

  12. It is unknown that dysglycemia in obese adolescents has effects on myocardial deformation that are more pronounced when compared to obesity alone. We hypothesized that obesity associated abnormal glucose toler...

    Authors: Preneet Cheema Brar, Anne Chun, Xiazhou Fan, Vivek Jani, Mary Craft, Puneet Bhatla and Shelby Kutty

    Citation: Cardiovascular Diabetology 2019 18:172

    Content type: Original investigation

    Published on:

  13. High-sensitivity troponin I (hs-Tnl) and B-type natriuretic peptide (BNP) are promising prognostic markers for coronary artery disease (CAD). This prospective cohort study investigated whether a combination of...

    Authors: Yuen-Kwun Wong, Chloe Y. Y. Cheung, Clara S. Tang, JoJo S. H. Hai, Chi-Ho Lee, Kui-Kai Lau, Ka-Wing Au, Bernard M. Y. Cheung, Pak-Chung Sham, Aimin Xu, Karen S. L. Lam and Hung-Fat Tse

    Citation: Cardiovascular Diabetology 2019 18:171

    Content type: Original investigation

    Published on:

  14. Glycemic variation has been suggested to be a risk factor for diabetes-related complications. Previous studies did not address confounding of diabetes duration, number of visits and length of follow-up. Here, ...

    Authors: Roderick C. Slieker, Amber A. W. H. van der Heijden, Giel Nijpels, Petra J. M. Elders, Leen M. ’t Hart and Joline W. J. Beulens

    Citation: Cardiovascular Diabetology 2019 18:170

    Content type: Original investigation

    Published on:

  15. HbA1c, the most commonly used indicator of chronic glucose metabolism, is closely associated with cardiovascular disease. However, the relationship between HbA1c and the mortality of acute coronary syndrome (A...

    Authors: Wenjun Pan, Haining Lu, Baotao Lian, Pengda Liao, Liheng Guo and Minzhou Zhang

    Citation: Cardiovascular Diabetology 2019 18:169

    Content type: Review

    Published on:

  16. The use of metformin after acute myocardial infarction (AMI) has been associated with reduced mortality in people with type 2 diabetes mellitus (T2DM). However, it is not known if it is acutely cardioprotectiv...

    Authors: Daniel I. Bromage, Tom R. Godec, Mar Pujades-Rodriguez, Arturo Gonzalez-Izquierdo, S. Denaxas, Harry Hemingway and Derek M. Yellon

    Citation: Cardiovascular Diabetology 2019 18:168

    Content type: Original investigation

    Published on:

  17. Omentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. Recent studies indicate a paradoxical relationship ...

    Authors: Masami Nishimura, Tomoaki Morioka, Mariko Hayashi, Yoshinori Kakutani, Yuko Yamazaki, Masafumi Kurajoh, Katsuhito Mori, Shinya Fukumoto, Atsushi Shioi, Tetsuo Shoji, Masaaki Inaba and Masanori Emoto

    Citation: Cardiovascular Diabetology 2019 18:167

    Content type: Original investigation

    Published on:

  18. Type 2 diabetes mellitus (T2DM) is a major cause of heart failure (HF) with preserved ejection fraction (HFpEF), usually presenting as left ventricular (LV) diastolic dysfunction. Thus, LV diastolic function s...

    Authors: Shun Yokota, Hidekazu Tanaka, Yasuhide Mochizuki, Fumitaka Soga, Kentaro Yamashita, Yusuke Tanaka, Ayu Shono, Makiko Suzuki, Keiko Sumimoto, Jun Mukai, Makiko Suto, Hiroki Takada, Kensuke Matsumoto, Yushi Hirota, Wataru Ogawa and Ken-ichi Hirata

    Citation: Cardiovascular Diabetology 2019 18:166

    Content type: Original investigation

    Published on:

  19. Diabetes mellitus is an important risk factor for atrial fibrillation (AF) development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of type 2 diabetes mellitus (T2DM). Their ...

    Authors: Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li and Tong Liu

    Citation: Cardiovascular Diabetology 2019 18:165

    Content type: Original investigation

    Published on:

  20. Glucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; however, its counter-protective effects have also been suggested in patients with heart failure and the clear explanation for...

    Authors: Aya Shiraki, Jun-ichi Oyama, Toshiyuki Nishikido and Koichi Node

    Citation: Cardiovascular Diabetology 2019 18:164

    Content type: Original investigation

    Published on:

  21. Although beta blockers could increase the risk of hypoglycemia, the difference between subtypes on hypoglycemia and mortality have not been studied. This study sought to determine the relationship between type...

    Authors: Kathleen Dungan, Jennifer Merrill, Clarine Long and Philip Binkley

    Citation: Cardiovascular Diabetology 2019 18:163

    Content type: Original investigation

    Published on:

  22. Statin therapy reduces the risk of cardiovascular events across a broad spectrum of patients; however, it increases the risk of new-onset diabetes (NOD). Although the highest dose pitavastatin is considered to...

    Authors: Han Saem Jeong, Soon Jun Hong, Serhim Son, Hyonggin An, Hyungdon Kook, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu and Do-Sun Lim

    Citation: Cardiovascular Diabetology 2019 18:162

    Content type: Original investigation

    Published on:

  23. The main aims of this study were to describe trends and outcomes during admission for infective endocarditis (IE) in people ≥ 40 years old with or without type 2 diabetes distributed in five time-periods (2001...

    Authors: José M. de Miguel-Yanes, Rodrigo Jiménez-García, Valentín Hernández-Barrera, Javier de Miguel-Díez, Manuel Méndez-Bailón, Nuria Muñoz-Rivas, Napoleón Pérez-Farinós and Ana López-de-Andrés

    Citation: Cardiovascular Diabetology 2019 18:161

    Content type: Original investigation

    Published on:

  24. Controversies exist regarding the optimal blood pressure (BP) level that is safe and provides cardiovascular protection in patients with type 2 diabetes mellitus (T2DM) and coexistent coronary artery disease. ...

    Authors: Ying Shen, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Lin Lu, Feng Hua Ding and Wei Feng Shen

    Citation: Cardiovascular Diabetology 2019 18:160

    Content type: Review

    Published on:

  25. Microvascular complications (MC) have been claimed to increase the risk for cardiovascular disease in diabetic subjects. However, the effect of MC burden on the risk of major vascular outcomes and all-cause mo...

    Authors: Monia Garofolo, Elisa Gualdani, Rosa Giannarelli, Michele Aragona, Fabrizio Campi, Daniela Lucchesi, Giuseppe Daniele, Roberto Miccoli, Paolo Francesconi, Stefano Del Prato and Giuseppe Penno

    Citation: Cardiovascular Diabetology 2019 18:159

    Content type: Original investigation

    Published on:

  26. Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however re...

    Authors: Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda and Koichi Node

    Citation: Cardiovascular Diabetology 2019 18:158

    Content type: Original investigation

    Published on:

  27. Both type 1 and type 2 diabetes are well-established risk factors for cardiovascular disease and early mortality. However, few studies have directly compared the hazards of cardiovascular outcomes and prematur...

    Authors: You-Bin Lee, Kyungdo Han, Bongsung Kim, Seung-Eun Lee, Ji Eun Jun, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin and Jae Hyeon Kim

    Citation: Cardiovascular Diabetology 2019 18:157

    Content type: Original investigation

    Published on:

  28. Heart failure (HF) is a common cardiovascular complication of type 2 diabetes (T2D). This secondary analysis investigated baseline factors and treatment differences associated with risk of hospitalization for ...

    Authors: Richard E. Pratley, Mansoor Husain, Ildiko Lingvay, Thomas R. Pieber, Thomas Mark, Hans A. Saevereid, Daniel Vega Møller and Bernard Zinman

    Citation: Cardiovascular Diabetology 2019 18:156

    Content type: Original investigation

    Published on:

  29. Lower-extremity peripheral artery disease (LE-PAD) and coronary artery disease (CAD) are both pathologically rooted in atherosclerosis, and their shared clinical features regarding the exposure to cardiovascul...

    Authors: Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, Yoshimitsu Soga, Masahiko Fujihara, Toshiro Shinke, Tetsuya Amano and Yuji Ikari

    Citation: Cardiovascular Diabetology 2019 18:155

    Content type: Original investigation

    Published on:

  30. Prediabetes has recently been associated with subclinical atheromatous disease in the middle-aged population. Our aim was to characterize atheromatous plaque burden by the number of affected territories and th...

    Authors: Enric Sánchez, Àngels Betriu, Carolina López-Cano, Marta Hernández, Elvira Fernández, Francisco Purroy, Marcelino Bermúdez-López, Cristina Farràs-Sallés, Silvia Barril, Reinald Pamplona, Ferran Rius, Cristina Hernández, Rafael Simó and Albert Lecube

    Citation: Cardiovascular Diabetology 2019 18:154

    Content type: Original investigation

    Published on:

  31. Diabetes has been reported to be associated with carotid artery plaque (CAP). However, it remains unclear whether hemoglobin A1c (HbA1c) level, a marker for long-term glycemic status, is associated with altere...

    Authors: Renying Xu, Ting Zhang, Yanping Wan, Zhuping Fan and Xiang Gao

    Citation: Cardiovascular Diabetology 2019 18:153

    Content type: Original investigation

    Published on:

  32. Daily glucose variability may contribute to vascular complication development irrespective of mean glucose values. The incremental glucose peak (IGP) during an oral glucose tolerance test (OGTT) can be used as...

    Authors: Yuri D. Foreman, Martijn C. G. J. Brouwers, Tos T. J. M. Berendschot, Martien C. J. M. van Dongen, Simone J. P. M. Eussen, Marleen M. J. van Greevenbroek, Ronald M. A. Henry, Alfons J. H. M. Houben, Carla J. H. van der Kallen, Abraham A. Kroon, Koen D. Reesink, Miranda T. Schram, Nicolaas C. Schaper and Coen D. A. Stehouwer

    Citation: Cardiovascular Diabetology 2019 18:152

    Content type: Original investigation

    Published on:

  33. The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special intere...

    Authors: Cristina Razquin, Miguel Ruiz-Canela, Clary B. Clish, Jun Li, Estefania Toledo, Courtney Dennis, Liming Liang, Albert Salas-Huetos, Kerry A. Pierce, Marta Guasch-Ferré, Dolores Corella, Emilio Ros, Ramon Estruch, Enrique Gómez-Gracia, Montse Fitó, Jose Lapetra…

    Citation: Cardiovascular Diabetology 2019 18:151

    Content type: Original investigation

    Published on:

  34. Insulin resistance (IR) is considered a pivotal risk factor for cardiometabolic diseases, and the triglyceride–glucose index (TyG index) has emerged as a reliable surrogate marker of IR. Although several recen...

    Authors: Erfei Luo, Dong Wang, Gaoliang Yan, Yong Qiao, Bo Liu, Jiantong Hou and Chengchun Tang

    Citation: Cardiovascular Diabetology 2019 18:150

    Content type: Original investigation

    Published on:

  35. Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL...

    Authors: Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic and Lawrence A. Leiter

    Citation: Cardiovascular Diabetology 2019 18:149

    Content type: Original investigation

    Published on:

  36. Excessive reactive oxygen species from endothelial mitochondria in type 2 diabetes individuals (T2DM) may occur through multiple related mechanisms, including production of mitochondrial reactive oxygen specie...

    Authors: Mamatha Kakarla, Venkata K. Puppala, Sudhi Tyagi, Amberly Anger, Kathryn Repp, Jingli Wang, Rong Ying and Michael E. Widlansky

    Citation: Cardiovascular Diabetology 2019 18:148

    Content type: Original investigation

    Published on:

  37. Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help ...

    Authors: Annunziata Nusca, Dario Tuccinardi, Claudio Proscia, Rosetta Melfi, Silvia Manfrini, Antonio Nicolucci, Antonio Ceriello, Paolo Pozzilli, Gian Paolo Ussia, Francesco Grigioni and Germano Di Sciascio

    Citation: Cardiovascular Diabetology 2019 18:147

    Content type: Original investigation

    Published on:

  38. Reverse cholesterol transport (RCT) is an important cardioprotective mechanism and the decrease in cholesterol efflux can result in the dyslipidemia. Although liraglutide, a glucagon like peptide-1 analogue, h...

    Authors: Ya-Ru Wu, Xiao-Yun Shi, Chun-Yan Ma, Yue Zhang, Rui-Xia Xu and Jian-Jun Li

    Citation: Cardiovascular Diabetology 2019 18:146

    Content type: Original investigation

    Published on:

  39. Mortality attributable to heart failure remains high. The prevalence of heart failure in patients with diabetes mellitus ranges from 19 to 26%. It is estimated that up to 21.1 million adults in the United Stat...

    Authors: Marcello Ricardo Paulista Markus, Susanne Rospleszcz, Till Ittermann, Sebastian Edgar Baumeister, Sabine Schipf, Ulrike Siewert-Markus, Roberto Lorbeer, Corinna Storz, Violetta Ptushkina, Annette Peters, Christa Meisinger, Fabian Bamberg, Matthias Nauck, Martin Bahls, Henry Völzke, Stephan Burkhard Felix…

    Citation: Cardiovascular Diabetology 2019 18:145

    Content type: Original investigation

    Published on:

  40. Aim of this study was to evaluate the relationship of plasma PCSK9 with metabolic and inflammatory profile and coronary atherosclerotic burden in patients with suspected CAD enrolled in the EVINCI study.

    Authors: Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina and Danilo Neglia

    Citation: Cardiovascular Diabetology 2019 18:144

    Content type: Original investigation

    Published on:

  41. Excess fat deposition could induce phenotypic changes of perivascular adipose tissue (PVAT remodeling), which may promote the progression of atherosclerosis via modulation of adipocytokine secretion. However, ...

    Authors: Yusaku Mori, Michishige Terasaki, Munenori Hiromura, Tomomi Saito, Hideki Kushima, Masakazu Koshibu, Naoya Osaka, Makoto Ohara, Tomoyasu Fukui, Hirokazu Ohtaki, Hirano Tsutomu and Sho-ichi Yamagishi

    Citation: Cardiovascular Diabetology 2019 18:143

    Content type: Original investigation

    Published on:

  42. Hyperglycemia in the setting of an acute coronary syndrome (ACS) impacts short term outcomes, but little is known about longer term effects. We therefore designed this study to firstly determine the associatio...

    Authors: Patric Winzap, Allan Davies, Roland Klingenberg, Slayman Obeid, Marco Roffi, François Mach, Lorenz Räber, Stephan Windecker, Christian Templin, Fabian Nietlispach, David Nanchen, Baris Gencer, Olivier Muller, Christian M. Matter, Arnold von Eckardstein and Thomas F. Lüscher

    Citation: Cardiovascular Diabetology 2019 18:142

    Content type: Original investigation

    Published on:

  43. Long-term treatment with up to 1.8 mg liraglutide improves cardiovascular and all-cause mortality in patients with type 2 diabetes at high risk for cardiovascular disease (CVD) and is currently under investiga...

    Authors: Natia Peradze, Olivia M. Farr, Nikolaos Perakakis, Iolanda Lázaro, Aleix Sala-Vila and Christos S. Mantzoros

    Citation: Cardiovascular Diabetology 2019 18:141

    Content type: Original investigation

    Published on:

  44. Gestational diabetes mellitus (GDM) is defined as the presence of high blood glucose levels with the onset, or detected for the first time during pregnancy, as a result of increased insulin resistance. GDM may...

    Authors: A. Lorenzo-Almorós, T. Hang, C. Peiró, L. Soriano-Guillén, J. Egido, J. Tuñón and Ó. Lorenzo

    Citation: Cardiovascular Diabetology 2019 18:140

    Content type: Review

    Published on:

  45. The aim of the present study was to identify a threshold for the cholesterol level at which the risk of cardiovascular disease (CVD) begins to increase in people with type 2 diabetes mellitus (DM).

    Authors: Mee Kyoung Kim, Kyungdo Han, Han Na Joung, Ki-Hyun Baek, Ki-Ho Song and Hyuk-Sang Kwon

    Citation: Cardiovascular Diabetology 2019 18:139

    Content type: Original investigation

    Published on:

  46. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanism...

    Authors: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz and Rury R. Holman

    Citation: Cardiovascular Diabetology 2019 18:138

    Content type: Original investigation

    Published on:

  47. Visceral fat area (VFA) is a good surrogate marker of obesity-related disorders, such as hypertension, dyslipidemia and glucose intolerance. Although estimating the VFA by X-ray computed tomography (CT) is the...

    Authors: Yoko Omura-Ohata, Cheol Son, Hisashi Makino, Ryo Koezuka, Mayu Tochiya, Tamiko Tamanaha, Ichiro Kishimoto and Kiminori Hosoda

    Citation: Cardiovascular Diabetology 2019 18:137

    Content type: Original investigation

    Published on:

  48. Diabetes mellitus (DM) or pre-diabetes status is closely associated with features of vulnerable coronary lesions in patients with stable coronary heart disease or acute coronary syndrome. However, the associat...

    Authors: Zhaoxue Sheng, Peng Zhou, Chen Liu, Jiannan Li, Runzhen Chen, Jinying Zhou, Li Song, Hanjun Zhao and Hongbing Yan

    Citation: Cardiovascular Diabetology 2019 18:136

    Content type: Original investigation

    Published on:

  49. Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs wi...

    Authors: Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto and Rury R. Holman

    Citation: Cardiovascular Diabetology 2019 18:135

    Content type: Original investigation

    Published on:

  50. The aim of the present study is to examine the effects of free fatty acids (FFAs) on major cardiovascular events (MACEs) in patients with stable coronary artery disease (CAD) and different glucose metabolism s...

    Authors: Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Hui-Wen Zhang, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Ying Gao, Jing Sun, Qian Dong and Jian-Jun Li

    Citation: Cardiovascular Diabetology 2019 18:134

    Content type: Original investigation

    Published on:

journal logo
Submit manuscript

Annual Journal Metrics

Advertisement

Cardiovascular Diabetology

ISSN: 1475-2840